全文获取类型
收费全文 | 10029篇 |
免费 | 566篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 110篇 |
儿科学 | 222篇 |
妇产科学 | 190篇 |
基础医学 | 1296篇 |
口腔科学 | 258篇 |
临床医学 | 1031篇 |
内科学 | 2397篇 |
皮肤病学 | 113篇 |
神经病学 | 1147篇 |
特种医学 | 366篇 |
外科学 | 1672篇 |
综合类 | 12篇 |
预防医学 | 282篇 |
眼科学 | 102篇 |
药学 | 609篇 |
中国医学 | 12篇 |
肿瘤学 | 854篇 |
出版年
2023年 | 48篇 |
2022年 | 62篇 |
2021年 | 199篇 |
2020年 | 134篇 |
2019年 | 184篇 |
2018年 | 256篇 |
2017年 | 211篇 |
2016年 | 253篇 |
2015年 | 237篇 |
2014年 | 362篇 |
2013年 | 504篇 |
2012年 | 781篇 |
2011年 | 716篇 |
2010年 | 403篇 |
2009年 | 392篇 |
2008年 | 675篇 |
2007年 | 645篇 |
2006年 | 687篇 |
2005年 | 667篇 |
2004年 | 696篇 |
2003年 | 606篇 |
2002年 | 515篇 |
2001年 | 106篇 |
2000年 | 76篇 |
1999年 | 79篇 |
1998年 | 91篇 |
1997年 | 70篇 |
1996年 | 74篇 |
1995年 | 80篇 |
1994年 | 70篇 |
1993年 | 74篇 |
1992年 | 68篇 |
1991年 | 71篇 |
1990年 | 53篇 |
1989年 | 57篇 |
1988年 | 41篇 |
1987年 | 39篇 |
1986年 | 40篇 |
1985年 | 32篇 |
1984年 | 39篇 |
1983年 | 32篇 |
1982年 | 38篇 |
1981年 | 34篇 |
1980年 | 29篇 |
1979年 | 19篇 |
1978年 | 17篇 |
1977年 | 12篇 |
1975年 | 10篇 |
1974年 | 10篇 |
1970年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
1.
2.
3.
Olivari Davide De Giorgio Daria Staszewsky Lidia Irene Fumagalli Francesca Boccardo Antonio Novelli Deborah Manfredi Martina Babini Giovanni Luciani Anita Ruggeri Laura Magliocca Aurora Zani Davide Danilo Masson Serge Belloli Angelo Pravettoni Davide Maiocchi Giuseppe Latini Roberto Ristagno Giuseppe 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2022,36(4):727-738
Cardiovascular Drugs and Therapy - Available animal models of acute heart failure (AHF) and their limitations are discussed herein. A novel and preclinically relevant porcine model of decompensated... 相似文献
4.
Vieri Grandi Antonello Baldo Emilio Berti Pietro Quaglino Serena Rupoli Mauro Alaibac Silvia Alberti-Violetti Paolo Amerio Valeria Brazzelli Pier Luigi Bruni Piergiacomo Calzavara-Pinton Aurora Parodi Emanuele Cozzani Martina Burlando Maria Concetta Fargnoli Daniele Gambini Paolo Iacovelli Alessia Pacifico Caterina Longo Giuseppe Monfrecola Alberico Motolese Giorgio Mozzicafreddo Carlo Cota Paolo Pigatto Alessandro Pileri Paola Savoia Marco Simonacci Marina Venturini Annamaria Offidani Elisa Molinelli Michele Pellegrino Emanuele Trovato Roberta Piccinno Karl Lawrence Nicola Pimpinelli 《Photodermatology, photoimmunology & photomedicine》2021,37(4):334-342
5.
6.
Giorgio Gandaglia Guillaume Ploussard Massimo Valerio Agostino Mattei Cristian Fiori Nicola Fossati Armando Stabile Jean-Baptiste Beauval Bernard Malavaud Mathieu Roumiguié Daniele Robesti Paolo Dell’Oglio Marco Moschini Stefania Zamboni Arnas Rakauskas Francesco De Cobelli Francesco Porpiglia Francesco Montorsi Alberto Briganti 《European urology》2019,75(3):506-514
Background
Available models for predicting lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) might not be applicable to men diagnosed via magnetic resonance imaging (MRI)-targeted biopsies.Objective
To assess the accuracy of available tools to predict LNI and to develop a novel model for men diagnosed via MRI-targeted biopsies.Design, setting, and participants
A total of 497 patients diagnosed via MRI-targeted biopsies and treated with RP and extended pelvic lymph node dissection (ePLND) at five institutions were retrospectively identified.Outcome measurements and statistical analyses
Three available models predicting LNI were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analyses. A nomogram predicting LNI was developed and internally validated.Results and limitations
Overall, 62 patients (12.5%) had LNI. The median number of nodes removed was 15. The AUC for the Briganti 2012, Briganti 2017, and MSKCC nomograms was 82%, 82%, and 81%, respectively, and their calibration characteristics were suboptimal. A model including PSA, clinical stage and maximum diameter of the index lesion on multiparametric MRI (mpMRI), grade group on targeted biopsy, and the presence of clinically significant PCa on concomitant systematic biopsy had an AUC of 86% and represented the basis for a coefficient-based nomogram. This tool exhibited a higher AUC and higher net benefit compared to available models developed using standard biopsies. Using a cutoff of 7%, 244 ePLNDs (57%) would be spared and a lower number of LNIs would be missed compared to available nomograms (1.6% vs 4.6% vs 4.5% vs 4.2% for the new nomogram vs Briganti 2012 vs Briganti 2017 vs MSKCC).Conclusions
Available models predicting LNI are characterized by suboptimal accuracy and clinical net benefit for patients diagnosed via MRI-targeted biopsies. A novel nomogram including mpMRI and MRI-targeted biopsy data should be used to identify candidates for ePLND in this setting.Patient summary
We developed the first nomogram to predict lymph node invasion (LNI) in prostate cancer patients diagnosed via magnetic resonance imaging-targeted biopsy undergoing radical prostatectomy. Adoption of this model to identify candidates for extended pelvic lymph node dissection could avoid up to 60% of these procedures at the cost of missing only 1.6% patients with LNI. 相似文献7.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
8.
9.
Giorgio Rizzo Marco Lo Presti Cinzia Giannini Teresa Sibillano Antonella Milella Giusy Matzeu Roberta Musio Fiorenzo G. Omenetto Gianluca M. Farinola 《Macromolecular chemistry and physics.》2020,221(13)
Silk fibroin (SF) obtained from Bombyx mori cocoon is a very promising biopolymer. It can be processed from aqueous solutions to obtain many versatile scaffolds useful in optoelectronics, photonics, and biomedicine. Aqueous solutions are prepared by dissolving degummed fibroin with chaotropic agents and then purifying by dialysis. This work presents, for the first time, a solubilization protocol, involving CeCl3·7H2O as chaotropic salt in water and ethanol, that allows to regenerate SF under a fibrous form, unlike the standard Ajisawa’s method, which uses CaCl2 and allows to obtain aqueous gels. All the experimental analyses performed (SEM, XPS, WAXS, ATR‐FTIR, NMR) suggest that the fiber recovered preserves most of the morphological and structural features of the pristine SF and is doped with Ce(III) ions, that interact mainly with the oxygen atoms of C?O moieties and side‐chains of amino acids. Ce(III) doped SF could be the base for new luminescent materials. 相似文献
10.
Joseph O. Lloyd Kim I. Chisholm Beatrice Oehle Martyn G. Jones Bright N. Okine Adnan AL-Kaisy Giorgio Lambru Stephen B. McMahon Anna P. Andreou 《Neurotherapeutics》2020,17(4):1973
Single-pulse transcranial magnetic stimulation (sTMS) of the occipital cortex is an effective migraine treatment. However, its mechanism of action and cortical effects of sTMS in migraine are yet to be elucidated. Using calcium imaging and GCaMP-expressing mice, sTMS did not depolarise neurons and had no effect on vascular tone. Pre-treatment with sTMS, however, significantly affected some characteristics of the cortical spreading depression (CSD) wave, the correlate of migraine aura. sTMS inhibited spontaneous neuronal firing in the visual cortex in a dose-dependent manner and attenuated l-glutamate-evoked firing, but not in the presence of GABAA/B antagonists. In the CSD model, sTMS increased the CSD electrical threshold, but not in the presence of GABAA/B antagonists. We first report here that sTMS at intensities similar to those used in the treatment of migraine, unlike traditional sTMS applied in other neurological fields, does not excite cortical neurons but it reduces spontaneous cortical neuronal activity and suppresses the migraine aura biological substrate, potentially by interacting with GABAergic circuits.Electronic supplementary materialThe online version of this article (10.1007/s13311-020-00879-6) contains supplementary material, which is available to authorized users.Key Words: Migraine, transcranial magnetic stimulation, GABA, glutamate, cortex 相似文献